Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers ...
A second-generation cardiac myosin inhibitor showed promise for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in the phase II REDWOOD-HCM trial. In the dose-finding study, 10 weeks of ...
EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating ...
Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced new, interim results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655), the largest and longest ...
NEW ORLEANS, LA—Mavacamten (Camzyos; Bristol Myers Squibb) better reduces left ventricular outflow tract (LVOT) obstruction than placebo among adolescent patients with obstructive hypertrophic ...
The investigational, next-generation cardiac myosin inhibitor aficamten (previously CK-274, Cytokinetics) continues to show promise as a potential treatment for hypertrophic cardiomyopathy (HCM).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results